EXPLORE THE UNIVERSITY OF OXFORD'S WORLD-CLASS RESEARCH

1 entry found
1
Journal article icon
Journal article

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.

  • Innes, A, Beattie, R, Sergeant, R, et al.
  • 2013-10-01
File available icon
Peer reviewed icon
Link to publisher copy available icon
FILTER RESULTS

TO TOP